Breaking News, Financial News

Financial Report: Charles River Labs 3Q

Revenues up 5% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Labs 3Q 3Q Revenues: $292.1 million (+5%) 3Q Earnings: $31.2 million (+41%) YTD Revenues: $876.3 million (+3%) YTD Earnings: $84.7 million (+7%) Comments: Research Models and Services (RMS) segment sales were $173.4 million in the quarter, up 4%, driven primarily by the acquisitions of Vital River and Accugenix, as well as growth in the legacy Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $118.7 million, up 6%, driven by increa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters